JP Morgan Chase
TLX

JP Morgan Chase’s Telix Pharmaceuticals TLX Stock Holding History

JP Morgan Chase’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$514K Sell
57,348
-17,020
-23% -$130K ﹤0.01% 4994
2025
Q4 		$557K Buy
74,368
+49,013
+193% +$472K ﹤0.01% 4939
2025
Q3 		$243K Buy
+25,355
New +$311K ﹤0.01% 5417

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

JP Morgan Chase's TLX Position: Q1 2026 in Review

JP Morgan Chase reduced its Telix Pharmaceuticals (TLX) stake by 23% in Q1 2026, selling an estimated $130K and leaving 57,348 shares worth $514K. The position accounts for ﹤0.01% of the portfolio, ranked #4994.

JP Morgan Chase first reported a position in TLX in Q3 2025 and has held it in 3 quarters since. The position peaked at $557K in Q4 2025. 39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

  • JP Morgan Chase held 57,348 shares of Telix Pharmaceuticals worth $514K as of Q1 2026.
  • JP Morgan Chase sold 17,020 Telix Pharmaceuticals shares in Q1 2026, an estimated $130K.
  • Telix Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4994 holding.
  • JP Morgan Chase first reported a position in Telix Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • JP Morgan Chase's Telix Pharmaceuticals position peaked at $557K in Q4 2025.
  • 39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.